NeoGenomics is trading 4.35% up at $19.21 as management highlighted accelerating NGS and MRD growth at the Morgan Stanley Global Healthcare Conference.
- NGS revenue grew 26% in the first half of 2026, exceeding $250 million annualized.
- Management cited expanded Medicare coverage for RaDaR ST, potential margin expansion, and full-year 2026 free-cash-flow positivity.
- Broader markets are lower; healthcare is comparatively strong, with positive investor response, though the source did not explicitly link the exact intraday move to the presentation.